Brief: Chemours Q2 Adjusted EPS USD 0.58 Vs. IBES Estimate USD 0.46

The Chemours

05/08/2025 21:56

Overview

Chemours Q2 2025 net sales rise 4%, beating analyst expectations, per LSEG data

Adjusted EPS for Q2 2025 beats consensus at $0.58, per LSEG data

Co reports net loss due to litigation charges, adjusted EBITDA beats estimates

Outlook

Chemours expects Q3 net sales to decrease 4-6% sequentially

Company anticipates Q3 adjusted EBITDA between $175 mln and $195 mln

Chemours forecasts full-year net sales of $5.9 bln to $6.0 bln

Company sees full-year adjusted EBITDA of $775 mln to $825 mln

Result Drivers

OPTEON™ REFRIGERANTS - Strong demand for Opteon™ Refrigerants drove sales growth in Thermal & Specialized Solutions

PRICING STRATEGY - Favorable pricing in Advanced Performance Materials contributed to sales increase

LITIGATION CHARGES - Net loss primarily due to litigation-related charges from settlement with New Jersey

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$1.60 bln
$1.56 bln (6 Analysts)
Q2 Adjusted EPS
Beat
$0.58
$0.46 (9 Analysts)
Q2 Adjusted EBITDA
Beat
$253 mln
$224 mln (6 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the diversified chemicals peer group is "buy."

Wall Street's median 12-month price target for Chemours Co is $15.00, about 15.8% above its August 5 closing price of $12.63

The stock recently traded at 6 times the next 12-month earnings vs. a P/E of 6 three months ago

Press Release: ID:nBw9t93Fja

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)